ArticleAmerican journal of translational research2025
Retrospective analysis of the impact of pathogen spectrum and antibiotic resistance on the treatment efficacy of respiratory tract infections from 2012 to 2022.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the impact of pathogen spectrum and antibiotic resistance on the treatment efficacy of clinical microbial infections from 2012 to 2022.
methodsRetrospective analysis of clinical data from 1200 patients with microbial infections admitted to The Fifth Hospital of Xiamen. Bacterial cultures and drug sensitivity tests were conducted, and the efficacy of first-line antibiotics was evaluated.
resultsA total of 1258 pathogens were identified, with 57.23% Gram-positive and 37.84% Gram-negative bacteria. Staphylococcus aureus and Staphylococcus epidermidis showed high resistance to penicillin and cephalosporins. Klebsiella pneumoniae and Escherichia coli exhibited elevated resistance to imipenem and cephalosporins. From 2018 to 2022, there was an increase in resistance to cephalosporins and a decrease in treatment efficacy (
conclusionsRising resistance rates to cephalosporins among Gram-positive and Gram-negative bacteria have led to diminished antibiotic efficacy. Adjustments in antibiotic selection, such as using glycopeptide antibiotics, are needed to combat resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.